Get the Daily Brief
Latest Biotech News
Anterior Raises $40M—AI Platform to Slash Care‑Approval Times
Anterior closed a $40 million financing to scale an AI platform that automates administrative clinical workflows for health plans, the company said. The platform is designed to accelerate...
Australia Launches World‑First Pediatric mRNA Brain‑Cancer Trial
Australia has launched Paedneo‑Vax, the first multisite pediatric trial testing individualized mRNA vaccines for aggressive childhood brain tumors. Funded by Providence Therapeutics with public...
Vertex’s CRISPR Therapy Rebounds—Casgevy Sales Triple in Latest Quarter
Vertex reported a significant sales increase for Casgevy, its CRISPR‑based gene therapy developed with CRISPR Therapeutics, with quarterly sales more than tripling versus the prior quarter....
VCs Launch European Life Science Coalition: €24B to Mobilize Investment
A consortium of venture capital firms and research institutions has formed the European Life Science Coalition to boost private and public investment into Europe’s biotech sector. The...
FDA rejects Disc therapy — expedited voucher route falters
The FDA rejected Disc Medicine’s bitopertin application, marking a high-profile rebuke of a rare-disease submission that had been expedited under a new priority-review voucher program. STAT...
NIAID reshapes priorities: biodefense and pandemic preparedness deprioritized
Internal directives at NIAID instructed staff to remove the terms “biodefense” and “pandemic preparedness” from public materials as the institute refocuses funding toward basic immunology and...
BridgeBio’s oral FGFR3 matches Voxzogo on height — adds pill option
BridgeBio reported that infigratinib, an oral FGFR3 inhibitor, produced height gains comparable to Voxzogo in trials for achondroplasia while offering an oral dosing option. BioCentury’s reporting...
Lyell launches head-to-head CAR-T trial: experimental therapy to face rivals
Lyell Immunopharma initiated a first-of-its-kind clinical trial testing its experimental CAR-T therapy directly against marketed CAR-T products, the company said. The trial will evaluate...
Quantx closes $85M Series B to advance oral immunology pipeline
Quantx Biosciences completed an $85 million Series B round to advance two oral immunology candidates toward the clinic: a STAT6 inhibitor and an IL-17 inhibitor. The company said the financing...
Australia launches world‑first pediatric mRNA brain‑cancer vaccine trial
Australia initiated Paedneo‑Vax, the first multisite pediatric trial testing individualized mRNA vaccines for children with aggressive brain tumors, funded by Providence Therapeutics and...
All of Us hits 1M participants — national diverse cohort complete
The NIH’s All of Us research program reached its recruitment goal of one million participants, delivering a cohort designed to reflect the diversity of the U.S. population. NIH reported the...
10x braces for modest growth — imaging‑free spatial tools advance
10x Genomics projected up to 4% revenue growth for 2026 and warned that constrained capital spending among customers will continue to pressure instrument revenue, while consumables demand —...
FDA declines to review Moderna flu shot — regulatory uncertainty ripples
The FDA declined to accept Moderna’s mRNA influenza vaccine for review, creating fresh regulatory uncertainty for mRNA platforms beyond COVID‑19 and prompting industry concern about shifting...
Gilead buys Genhouse cancer drug: $80M upfront for global rights
Gilead agreed to acquire global rights to an oral oncology candidate from China‑based Genhouse Bio for $80 million up front, a deal announced as Genhouse pursues a Hong Kong IPO. The transaction...
FDA rejects Disc’s bitopertin: Voucher-backed rare-disease bid fails
The FDA issued a rejection letter for Disc Medicine’s bitopertin, the company’s experimental therapy for porphyria, after questioning the link between the trial’s blood biomarker and meaningful...
PTC pulls Translarna: Two-decade Duchenne bid stalls
PTC Therapeutics announced it will not pursue FDA approval for Translarna (ataluren) in Duchenne muscular dystrophy after regulators signaled the submitted data were unlikely to meet the agency’s...
FDA balks at Moderna flu: Review refused – industry on edge
The FDA declined to accept Moderna’s application for its mRNA influenza vaccine, an unexpected regulatory rebuff that has rippled through biotech markets. STAT’s reporting captured industry...
NIAID shifts focus: 'Biodefense' and pandemic preparedness deprioritized
Internal communication obtained by Nature shows the National Institute of Allergy and Infectious Diseases (NIAID) has directed staff to remove references to 'biodefense' and 'pandemic...
Lyell launches head-to-head CAR‑T trial: First-of-its-kind test
Lyell Immunopharma opened a randomized, head-to-head CAR‑T trial that will pit its experimental product directly against marketed cell therapies. The trial is notable for testing a next-generation...
Australia launches first pediatric mRNA brain-cancer trial
Australia began the Paedneo‑Vax trial, the first multisite pediatric study testing individualized mRNA vaccines for aggressive childhood brain tumors. The trial is funded by Providence...